Published in Infect Immun on February 01, 1998
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev (2012) 1.45
Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio (2012) 1.28
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Role of the mannose receptor in a murine model of Cryptococcus neoformans infection. Infect Immun (2008) 1.17
The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect Immun (1999) 1.11
Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun (2001) 1.08
Early induction of interleukin-12 by human monocytes exposed to Cryptococcus neoformans mannoproteins. Infect Immun (2000) 1.06
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
Cryptococcus neoformans histone acetyltransferase Gcn5 regulates fungal adaptation to the host. Eukaryot Cell (2010) 1.00
Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun (2004) 1.00
Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan. Immunology (2004) 0.94
Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect Immun (2010) 0.92
Capsular Material of Cryptococcus neoformans: Virulence and Much More. Mycopathologia (2012) 0.90
Glycoconjugates and polysaccharides of fungal cell wall and activation of immune system. Braz J Microbiol (2008) 0.85
The role of host gender in the pathogenesis of Cryptococcus neoformans infections. PLoS One (2013) 0.84
A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis. J Infect Dis (2016) 0.84
Rat eosinophils stimulate the expansion of Cryptococcus neoformans-specific CD4(+) and CD8(+) T cells with a T-helper 1 profile. Immunology (2010) 0.84
B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology (1999) 0.83
Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Immunology (2002) 0.81
A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide. Clin Exp Immunol (2011) 0.80
Macrophage mitochondrial and stress response to ingestion of Cryptococcus neoformans. J Immunol (2015) 0.79
The CSF immune response in HIV-1-associated cryptococcal meningitis: macrophage activation, correlates of disease severity and effect of antiretroviral therapy. J Acquir Immune Defic Syndr (2017) 0.75
The environmental yeast Cryptococcus liquefaciens produces capsular and secreted polysaccharides with similar pathogenic properties to those of C. neoformans. Sci Rep (2017) 0.75
Immune correlates of HIV-associated cryptococcal meningitis. PLoS Pathog (2017) 0.75
Rim Pathway-Mediated Alterations in the Fungal Cell Wall Influence Immune Recognition and Inflammation. MBio (2017) 0.75
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med (1974) 6.75
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol (1982) 3.92
Cryptococcus neoformans. 3. Inhibition of phagocytosis. J Bacteriol (1968) 3.48
Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect Immun (1976) 3.41
Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med (1986) 3.34
Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol (1980) 2.98
Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect Immun (1977) 2.84
Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol (1982) 2.36
Primary responses of human T cells to mycobacteria: a frequent set of gamma/delta T cells are stimulated by protease-resistant ligands. Eur J Immunol (1990) 2.25
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect Immun (1986) 1.88
Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun (1995) 1.86
Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun (1991) 1.80
Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect Immun (1989) 1.76
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun (1996) 1.71
Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect Immun (1994) 1.57
Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun (1991) 1.54
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun (1996) 1.53
Binding of cryptococcal polysaccharide to Cryptococcus neoformans. Infect Immun (1984) 1.52
Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells. J Immunol (1983) 1.52
Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.51
Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol (1994) 1.51
Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2). J Immunol (1985) 1.48
Antibody-dependent leukocyte killing of Cryptococcus neoformans. J Immunol (1983) 1.47
Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun (1997) 1.41
Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s). Infect Immun (1987) 1.39
Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1992) 1.38
Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol (1994) 1.37
Effects of first-order Cryptococcus-specific T-suppressor cells on induction of cells responsible for delayed-type hypersensitivity. Infect Immun (1985) 1.34
Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants. Infect Immun (1986) 1.20
Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide. Infect Immun (1996) 1.18
Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect Immun (1993) 1.15
Inhibition of candidacidal activity of polymorphonuclear cells by alveolar macrophage-derived factor from lung cancer patients. Am Rev Respir Dis (1993) 1.05
Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum. Clin Exp Immunol (1987) 1.00
Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen. Clin Exp Immunol (1988) 0.99
Cryptococcal infections in patients with AIDS. N Engl J Med (1990) 0.98
Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clin Exp Immunol (1997) 0.92
Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Res Hum Retroviruses (1994) 0.91
Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J Med Vet Mycol (1996) 0.86
Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol (1990) 4.37
The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol (1982) 3.92
Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect Immun (1976) 3.41
Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect Immun (1977) 2.84
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun (1987) 2.50
Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun (1991) 2.46
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med (1996) 2.41
Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J Exp Med (1992) 2.37
Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun (1984) 2.30
CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol (1993) 2.30
An immunohistochemical method that differentiates Cryptococcus neoformans varieties and serotypes in formalin-fixed paraffin-embedded tissues. Med Mycol (2001) 2.16
Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun (1988) 2.11
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol (1993) 2.05
Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect Immun (1979) 2.01
Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun (1977) 1.93
Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun (1990) 1.89
Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect Immun (1986) 1.88
Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect Immun (1989) 1.87
Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun (1986) 1.86
Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun (1995) 1.86
An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol (1997) 1.76
IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol (2010) 1.76
IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol (1994) 1.75
Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun (1990) 1.72
Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol (1994) 1.72
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun (1996) 1.71
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect Immun (1981) 1.68
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun (1994) 1.68
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol (1997) 1.68
Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect Immun (1980) 1.65
Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect Immun (1979) 1.65
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
Induction of humoral antibody response by soluble polysaccharide of Cryptococcus neoformans. Mycopathol Mycol Appl (1974) 1.61
Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun (1997) 1.61
Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun (1989) 1.56
Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun (1993) 1.56
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun (1996) 1.53
Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res (2001) 1.52
Binding of cryptococcal polysaccharide to Cryptococcus neoformans. Infect Immun (1984) 1.52
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol (2002) 1.51
Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.51
Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol (1994) 1.51
Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody. Infect Immun (1972) 1.50
In vitro production of tumor necrosis factor by murine splenic macrophages stimulated with mannoprotein constituents of Candida albicans cell wall. Cell Immunol (1991) 1.49
T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol (2000) 1.48
Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol (2001) 1.48
The A-domain and the thrombospondin-related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands. EMBO J (1999) 1.47
Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. Infect Immun (1983) 1.43
Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J (1994) 1.42
Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun (1992) 1.41
T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis (1995) 1.41
Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect Immun (1979) 1.39
Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun (2000) 1.39
Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol (2000) 1.39
Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. J Gen Microbiol (1988) 1.38
Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol (1994) 1.37
Extracellular deoxyribonuclease production by yeasts. J Bacteriol (1969) 1.37
Two conserved amino acid motifs mediate protein targeting to the micronemes of the apicomplexan parasite Toxoplasma gondii. Mol Cell Biol (2000) 1.36
Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.34
Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur J Immunol (1994) 1.33
Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule. Infect Immun (1995) 1.31
In vitro natural cell-mediated cytotoxicity against Candida albicans: macrophage precursors as effector cells. J Immunol (1985) 1.30
T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol (1990) 1.29
Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J Neuroimmunol (1995) 1.28
S100B expression in and effects on microglia. Glia (2001) 1.28
Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol (1995) 1.27
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun (1997) 1.27
Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect Immun (1994) 1.26
Serodiagnosis of infectious diseases with antigen microarrays. J Appl Microbiol (2004) 1.25
Immunosuppressive effect of cyclosporin A on resistance to systemic infection with Candida albicans. J Med Microbiol (1989) 1.25
In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J Infect Dis (2001) 1.24
Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol (1989) 1.21
Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. Infect Immun (1983) 1.20
Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages. Infect Immun (1978) 1.20
A comparison of experimental pathogenicity of Candida species in cyclophosphamide-immunodepressed mice. Sabouraudia (1984) 1.19
Gamma interferon modifies CD4+ subset expression in murine candidiasis. Infect Immun (1992) 1.19
Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis (1999) 1.19
Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis (1994) 1.19
Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis (1997) 1.19
Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. J Med Vet Mycol (1988) 1.18
CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun (1996) 1.18
Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother (1985) 1.18
Activation and binding of C3 by Candida albicans. Infect Immun (1987) 1.17
Increase of mouse resistance to Candida albicans infection by thymosin alpha 1. Infect Immun (1982) 1.13
A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol (1995) 1.12
Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect Immun (1997) 1.12